Equities research analysts expect Evolus Inc (NASDAQ:EOLS) to report ($0.96) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Evolus’ earnings. The highest EPS estimate is ($0.82) and the lowest is ($1.10). Evolus reported earnings per share of ($0.46) during the same quarter last year, which suggests a negative year over year growth rate of 108.7%. The company is expected to announce its next quarterly earnings results on Monday, March 16th.

On average, analysts expect that Evolus will report full year earnings of ($3.25) per share for the current financial year, with EPS estimates ranging from ($3.64) to ($2.94). For the next financial year, analysts forecast that the business will report earnings of ($2.15) per share, with EPS estimates ranging from ($2.48) to ($1.64). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Evolus.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.78) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.33) by $0.55. The company had revenue of $13.17 million during the quarter, compared to analysts’ expectations of $5.18 million.

A number of research firms have issued reports on EOLS. JMP Securities reduced their price target on shares of Evolus from $35.00 to $30.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 13th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Evolus from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright reissued a “buy” rating on shares of Evolus in a research report on Tuesday. Stifel Nicolaus set a $33.00 price target on shares of Evolus and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, ValuEngine raised shares of Evolus from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. Evolus currently has a consensus rating of “Buy” and an average price target of $26.67.

Several large investors have recently bought and sold shares of EOLS. Metropolitan Life Insurance Co NY purchased a new position in shares of Evolus during the 1st quarter valued at approximately $83,000. Valeo Financial Advisors LLC increased its holdings in shares of Evolus by 52.1% during the 2nd quarter. Valeo Financial Advisors LLC now owns 7,300 shares of the company’s stock valued at $107,000 after purchasing an additional 2,500 shares in the last quarter. Edge Wealth Management LLC purchased a new position in shares of Evolus during the 2nd quarter valued at approximately $29,000. Segantii Capital Management Ltd acquired a new stake in Evolus in the 2nd quarter valued at $1,097,000. Finally, Creative Planning acquired a new stake in Evolus in the 2nd quarter valued at $318,000. 18.66% of the stock is owned by hedge funds and other institutional investors.

Evolus stock traded down $0.86 during midday trading on Friday, hitting $14.23. 840,100 shares of the company’s stock were exchanged, compared to its average volume of 773,062. Evolus has a 12 month low of $10.22 and a 12 month high of $30.25. The company has a debt-to-equity ratio of 4.53, a quick ratio of 4.51 and a current ratio of 3.66. The company has a market cap of $427.56 million, a PE ratio of -9.06 and a beta of 4.68. The firm has a 50-day moving average of $15.73 and a two-hundred day moving average of $16.86.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Read More: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.